Copenhagen, Denmark—As first-line single-agent hormone therapy, fulvestrant provides more durable disease control than anastrozole in postmenopausal patients with estrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic inoperable breast cancer, according to a multicenter, Phase III trial. The advantage of fulvestrant was greatest in those with nonvisceral disease.
In the patients who derived the most benefit in this study, “it looks like fulvestrant could be a